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enrichment. This is an important point becaus th
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suggestions that CHWs should beco·me mo f II
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Integrated In.to the health system, possibly as enrolled
nurses. Turning CHWs into community nurses would be a
retrograde step not in line with the true concept and ideals
of primary health care.
In our h~alth wards we have come to appreciate the value
of our motivated and energetic CHWs more and Th
. . . more. ey
ar.e an Inspiring group of women to work with. Community
cliniC nurses state that CHWs are more effective at delivering
basIc health education than they are, and clinics operating in
areas Without CHWs continually ask us when the CHW
programme will be extended into their area. Their role in
promoting healthy sexual behaviour, family planning and safe
motherhood, preve~ting malnutrition and encouraging
rational health seeking behaviour is potentially massive.
Anyone who doubts the effectiveness, value and
releva~ce of CHWs to South Africa need only spend some
time With them In our communities.
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Dr N. C. Dlamini Zuma, Minister of Health, comments:
Or McCoy et al. allege that I indicated that 'community
health worker (CHW) programmes may be phased out, or at
best, not further expanded'. This is not a true reflection of
what I said.
Firstly I never addressed the topic of CHWs in my speech,
but twice during meetings in Natal I was asked questions on
CHWsafter finishing it. Secondly I did not say that CHW
programmes must be phased out or not further expanded.
What I did say (and the audience agreed with this) was that
we cannot build a health care system on CHWs. The basis
on which to build the health care system is a clinic staffed
by health professionals. In South Africa these are usually
nurses, because so few of our primary health care facilities
have full-time medical practitioners. Once we have the
health professionals in place we can look at CHW
programmes. I accept the complementary role CHWs can
play in health care.
I fully agree with the authors that under no circumstances
should CHWs become enrolled nurses. This will certainly
erode their unique place in the health care team.
Furthermore, CHWs function at a local or provincial level. It
would be a mistake if the National Department were to try to
be prescriptive in this regard. Defining the role of CHWs will
therefore be a local and definitely not a national decision.
Recurrent herpes zoster and high-dose
inhaled steroids for asthma
To the Editor: A 31-year-old woman who used
beclomethasone 2 000 ~g/d to control her severe asthma
had 4 episodes of herpes zoster over a period of 18 months,
all over the same dermatomal distribution at the right
buttock. These episodes were not associated with booster
doses of oral steroids. Investigations found no other causes
of immune suppression. Her serum cortisol level was
normal, as was urinary cortisol over a 24-hour period, thus
excluding adrenal insufficiency.
On enquiring of the Medicines Control Council whether
this is a recognised side-effect of high-dose inhaled steroids
(it is well known to be a complication of parenteral or oral
steroid use), we were told that no case has been reported so
far.
We consider that there is a definite association between
this patient's high-dose inhaled steroid use 'and her herpes
zoster and that this should perhaps be included in a list of
possible side-effects of high-dose inhaled steroid therapy,
and have forwarded a copy of this letter to the Medicines
Control Council.
The patient is now on high-dose inhaled fluticasone.
A. H. Bruning
M. H. 5amie
313A Gatesville Medical Centre
Gatesville, W. Cape
Steroid-induced osteoporosis
To the Editor: Kalla et al. ' recently published their work on
the effect of glucocorticoid (GC) therapy on the bone mass
of 'patients with rheumatoid arthritis (RA) and systemic lupus
erythematosus (SLE). They made the interesting observation
that cortical bone mass was significantly lower in patients
with RA than in those with SLE, although the latter required
larger cumulative doses of GC for longer periods.
Individual sensitivity of skeletal tissue to GC is well
known, and a number of 'risk factors'for steroid-induced
osteoporosis have been suggested, including a high total
cumulative steroid dose, long duration of GC therapy, age
under 15 or over 50 years, postmenopausal status, general
risk factors for osteoporosis, and disorders associated with
increased interleukin-1, interleukin-6 or tumour necrosis
factor (TNF) production, e.g. rheumatoid arthritis.'" Kalla
et al. suggest that their observation that patients with SLE
are protected against the development of steroid-induced
osteoporosis may be explained in part by the recent
demonstration that patients with SLE have lower circulating
levels of TNF - an interesting hypothesis deserving of
further study.
The authors also conclude that the influence of GC
therapy on bone is controversial and that bone loss in RA
and SLE is more likely to represent an effect of the
underlying disease than a complication of chronic GC
therapy. Whereas an individual sensitivity to steroids as well
as a primary disease effect on bone have been aptly
documented, recent reports indicate that there can be no
doubt as to the potential deleterious effects of long-term GC
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therapy on skeletal integrity."'2 Moreover, it is now firmly
established that GC, like numerous other causes of
osteoporosis including early post-menopausal (type 1)
osteoporosis, predominantly involve trabecular bone, with
sparing of the cortical bone of the metacarpals and to a
lesser degree the femoral neck. This may relate, at least in
part, to the fact that trabecular bone is 8 times more
metabolically active than cortical bone, and hence more
prone to injury. Older techniques, including radiogrammetry,
employed in the present study to measure appendicular
bone mass, have therefore often underestimated steroid-
induced bone loss.
Employing dual energy X-ray absorptiometry (DXA) to
measure axial bone mass in 111 atopic asthmatic patients
(60 on GC; 51 non-GC), we have also recently documented
significant osteopenia, predominantly involving the spine, in
48% of steroid-treated subjects." No correlation existed
between bone mass and steroid dose/duration of therapy,
gender, menopausal status, presence of conventional risk
factors, cushingoid side-effects or serum biochemical
measurements including cortisol binding globulin levels. In
fact only basal and 1,25(OH)2 vitamin D-stimulated
osteocalcin kinetics differed between steroid-treated
patients with a normal and those with a decreased bone
mass, suggesting individual sensitivity to steroids at an
osteoblast level.
It is therefore fair to conclude that long-term GC therapy
should be regarded as a common and important cause of
osteoporosis. The development of bone loss is not
necessarily dose-dependent or readily predictable; even
low-dose GC therapy in RA has recently been shown to
result in a 3-fold higher fracture rate than in RA patients not
receiving GC.'2 Whereas patients who need it should
certainly not be deprived of GC therapy, awareness that it
may cause bone loss and early prophylaxis are required.
F. S. Hough
Chairman: National Osteoporosis Foundation
Department of Endocrinology and Metabolism
University of Stellenbosch
Tygerberg. W. Cape
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Or KaIJa, Professor Meyers and Or Laubscher reply: It was
not our intention to encourage a cavalier approach to the
use of GC therapy, but rather to report the interesting
findings we observed in our study of two disease
populations. We believe the following points need to be
made in response to the above letter.
1. We agree that cortical bone may differ from trabecular
bone in the manifestation of osteopenia owing to differences
in their metabolic activities. However, some studies show
equal effects of GC on cortical and trabecular bone.' It is
also interesting that some diseases, like RA, may cause
severe cortical bone loss with less impressive trabecular
bone loss.2 In the experimental situation, osteoclast and
osteoblast responses are identical when subjected to local
and systemic influences, irrespective of their origin.
2. The studies quoted above need to be interpreted with
caution, since a large proportion of GC patients have l:>een
postmenopausal. The effects of GC seem to be worse in
postmenopausal subjects (oestrogen deficiency), and it is
not always clear how much is the additional effect of GC.
Guyatt et al. 3 have elaborated the many problems with
earlier studies, some of which have been addressed. in
subsequent research. '.
3. The author refers to experience with DXA in GC-
dependent asthma patients whose bone mineral deosity
(BMD) was significantly reduced. He does not provide
information regarding menopausal status, physical activity or
severity of the asthma, all of which could independently
contribute to bone loss. We consider that it is extremely
difficult to find adequate controls for this kind of research,
since GC-treated diseases could interfere with BMD by
several mechanisms. While asthma, SLE and RA may have
in common the need for GC therapy, they differ significantly
from each other in many other respects; in particular,
cytokine activity is different! Our selection of RA and SLE
for comparison was based on their common auto-immune
background and their wide difference in GC dosage
requirements. They clearly differ significantly in the extent of
disability they cause. It is interesting that Professor Hough
was unable to show any relationship in asthma between GC
daily dose or duration of cumulative therapy.
4. We are aware of the controversies relating to the
effects of GC on cortical bone, and have extended our
studies to include trabecular BMD measurement in SLE.5
Again we were unable to show any significant effect on
lumbar or femoral BMD in premenopausal SLE patients
receiving high-dose (1 mg/kg/d in reducing doses for more
than 6 months) GC therapy. The data showed that the
underlying disease was likely to be the major cause of bone
loss. Similar results in SLE have been reported by others." It
is possible that GC is simply a surrogate measure of severe
disease rather than a pathogenetic factor in bone loss..
5. We would also caution against assuming that
statistically significant differences necessarily translate to
clinically significant differences. Sambrook et al.] are the
only workers to have shown a prophylactic effect of calcitriol
in GC osteoporosis.] Other work on postmenopausal
subjects failed to show a beneficial effect of vitamin 0 and
calcium supplementation,· but antiresorptive agents may be
of some use. The use of deflazacort as a bone-sparing GC
is encouraging, but controversy rages about the equivalent
anti-inflammatory effect.9 We would certainly encourage
prophylactic therapy aimed at reducing fracture
complications of osteoporosis.
6. We would argue, therefore, that it is not fair to
conclude that GC causes bone loss under all circumstances.
Unfortunately, experimental conditions are never able to
Volume 84 No. 12 December 1994 SAMJ
B R EWE
simulate the in vivo milieu in its entirety. Therefore, such
results should be interpreted with caution. It is ironical that
bone loss is thought to be due to osteoclast activating
factors which are negatively influenced by GC, suggesting,
in theory, that GC should protect against bone loss due to
cytokine activity.
In conclusion, we agree that diligent awareness and early
prophylaxis against bone loss are essential when initiating
treatment with GC. Perhaps DXA measurement of BMD
should be the reference standard for such decisions
particularly since rheumatic diseases may influence ~any of
the metabolic markers of bone and cartilage metabolism.'.
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Electrotherapy for snakebite
To the Editor: In 1988 the index catalogue of the library of
the Surgeon General's office (US Army) listed over 500
references on the use of electrotherapy for bites and stings.
Guderian et aI. ' in a letter to the Lancet (1986) presented
34 cases of Ecuadorian snakebite. Twenty-five patients were
treated within 30 minutes of the bite by high-voltage (25 mV),
low-amperage (less than 1 mAl direct current, applied for
1 - 2 seconds at 5 - 10-second intervals for 4 - 5 shocks.
Such a current is found in a modified stun gun or a spark plug
of an outboard motor, lawnmower or auxiliary lighting plant.
Within 10 - 15 minutes there was no pain, no local or
systemic poisoning and no morbidity or mortality. Most
patients went home an hour later. Seven patients refused
treatment. All developed clinical poisoning and 2 required
amputations. A further 2 with established envenomation
were treated 2 hours after the event. Pain relief occurred in
30 minutes, and swelling did not progress and subsided
within 3 days.
These are very impressive results. Adverse comments
would include unknown age and gender of patients and
species of snake; lack of proper controls; natural selection
of patients (the very sick could not get to hospital); and a
highly selective group of patients, since snakebite is so
common, causing high immunity in the community! A
possible mechanism of action was postulated. Venom has a
short half-life, and electrospasm of local vessels contained
the venom long enough for it to be degraded and hence
inactive. However, Christensen3 in 1955 showed that both
wet and dry South African snake venom in vitro had an
extremely long half-life, measured in months.
In vivo the half-life is much shorter. Venom action
continues for 3 - 4 days if swelling is the clinical
presentation, and for several days in Cape cobra (Naja nivea)
and boomslang (Dispholidus typus) bites.
Reitz et al. 4 showed in 1987 that a similar electric current
had no effect on morbidity and mortality in rats injected with
pretreated or untreated venom of N. haje (Egyptian cobra) or
N. mossambica (spitting cobra) compared with controls. No
change in the composition of the venoms could be detected
by electrophoresis after exposure to the current in vitro.
Likewise, Howe et aI. 5 injected Bothrops atrox (Ecuadorian
pit viper) venom subcutaneously in increasing doses into rats,
half of which received electrotherapy. There was no difference
in morbidity and mortality between the two groups.
Rats are not human, but it is unlikely that electrotherapy
will be found more beneficial than placebo in the
management of snakebite.
R. S. Blaylock
Leslie Williams Memorial Hospital
Carletonville, North-West
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Centre for behavioural sciences founded
at the University of the Orange Free State
To the Editor: Although the Departments of Psychiatry and
Psychology at the University of the Orange Free State have
always set an example with their outstanding working
relationship, it was felt that this collaboration should be
formalised in order to increase research output and in the
process also improve training. It was assumed that, since
the two sciences have so much in common, not only the
output but also the quality of research could be increased
by founding· a research centre. The final decision to go
ahead with a Centre for Behavioural Sciences (a nationally
and internationally recognised concept) was triggered by the
Department of Psychiatry's prominent role in community
service, which underlined the urgent need for research in
this regard. Discussions between members of the
Department of Psychology and community leaders
emphasised this need.
In October 1993 the Centre for Behavioural Sciences -
which can be regarded as a research bridge between the
Departments of Psychiatry and Psychology - was finally
approved by the authorities of the University. The Executive
Committee consists of Professor C. A. Gagiano, head of the
Department of Psychiatry, and Professors S. J. Wessels and
D. A Louw from the Department of Psychology. Professor
Louw will be head of the Centre.
Since the main focus of the Centre will be on executing
high-quality research in communities, several potential
projects in this regard have already been identified. At
present the Centre is conducting an epidemiological stUdy
(using the new DSM-IV) and a situation analysis in
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